Grace Science

Grace Science LLC is a biomedical research and drug development company focused on rare genetic diseases, with initial emphasis on NGLY1 deficiency and plans for expansion into additional therapeutic areas. The company is built on a collaborative ecosystem of accomplished scientists, entrepreneurs, and industry veterans who bring deep expertise acr... oss drug discovery, development, and commercialization. Leadership includes a Silicon Valley entrepreneur and biomedical investor; a Stanford University professor and Howard Hughes Medical Institute investigator specializing in chemistry and chemical biology; a venture capitalist with foundational involvement in major life sciences companies including Regeneron Pharmaceuticals; and seasoned pharmaceutical executives with combined experience spanning rare genetic disease programs, gene therapy, protein therapeutics, oligonucleotide therapeutics, small molecules, and biomarker discovery. The company's Chief Scientific Officer brings over thirty years of R&D experience from leading pharmaceutical and biotech organizations, including prior leadership at BioMarin Pharmaceutical where he oversaw programs across multiple therapeutic modalities and rare disease indications. Additional team members contribute more than two decades of experience in drug development across all stagesfrom discovery through post-marketing approvalwith particular strength in rare disease therapeutics and global regulatory pathways. The team includes glycobiologists with specialized expertise in biomarker and therapeutic discovery for rare genetic diseases. Grace Science's distinctive model emphasizes breakthrough science through collaboration among individuals committed to advancing understanding and treatment of underserved genetic conditions. The company's foundation in both academic rigor and commercial drug development experience positions it to translate scientific discovery into viable therapeutics for patient populations with limited treatment options.Read More